ARS Pharmaceuticals Announces That It Will Be Launching The NeffyinSchools Program In January 2025; The Program Will Provide Eligible Public And Private K-12 Schools In The U.S. The Opportunity To Receive Two Cartons Of Neffy 2mg For Use In Emergency...
ARS Pharmaceuticals Announces That It Will Be Launching The NeffyinSchools Program In January 2025; The Program Will Provide Eligible Public And Private K-12 Schools In The U.S. The Opportunity To Receive Two Cartons Of Neffy 2mg For Use In Emergency...
Type 1 allergic reactions can be life-threatening, can happen in minutes, and can be caused by stinging and biting insects, foods, medication, exercise, or other unknown causes. Studies show that up to 18% of children with food allergies have had a reaction from accidentally eating food allergens while at school.1 In addition, 25% of severe and potentially life-threatening reactions (anaphylaxis) reported at schools happened in children with no previous diagnosis of food allergy.1 ARS Pharmaceuticals Announces That It Will Be Launching The NeffyinSchools Program In January 2025; The Program Will Provide Eligible Public And Private K-12 Schools In The U.S. The Opportunity To Receive Two Cartons Of Neffy 2mg For Use In Emergency Situations At No Cost To The School
ARS製藥公司宣佈將於2025年1月推出NeffyinSchools計劃；該計劃將爲美國符合條件的公立和私立K-12學校提供兩箱Neffy 2mg，用於緊急情況，學校無需支付任何費用。
Qualifying public and private K-12 Schools in the U.S. will be eligible to receive two free cartons (four single use doses) of neffy (epinephrine nasal spray) 2mg for use in emergency treatment of allergic reactions including anaphylaxis
美國符合資格的公立和私立K-12學校將有資格免費獲得兩箱（四個單次使用劑量）的neffy（腎上腺素鼻噴霧）2mg，用於應急治療過敏反應，包括過敏性休克。
Interested schools are encouraged to review applicable state laws and regulations to ensure neffy for undesignated use meets all requirements
有意向的學校被鼓勵查閱適用的州法律和法規，以確保neffy在未指定用途上的使用符合所有要求。
SAN DIEGO, Dec. 04, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, announced today that it will be launching the neffyinSchools Program in January 2025. The program will provide eligible public and private K-12 schools in the U.S. the opportunity to receive two cartons (four single use doses) of neffy (epinephrine nasal spray) 2mg for use in emergency situations at no cost to the school. neffy 2mg was recently approved for the treatment of Type I Allergic Reactions, including anaphylaxis, in adults and children who weigh ≥30 kg (66 lbs.) Participating schools will be eligible to receive replacement doses when the product is used or expires.
聖地亞哥，2024年12月4日（全球新聞通訊）——ARS製藥公司（納斯達克：SPRY），一家致力於賦權處於危機中的患者和護理者更好地保護自己免受可能導致過敏性休克的過敏反應的生物製藥公司，今天宣佈將於2025年1月推出neffyinSchools計劃。該計劃將爲美國符合條件的公立和私立K-12學校提供兩箱（四個單次使用劑量）的neffy（腎上腺素鼻噴霧）2mg，用於緊急情況，學校無需支付任何費用。neffy 2mg最近已被批准用於治療I型過敏反應，包括過敏性休克，適用於體重≥30 kg（66磅）的成年人和兒童。參加的學校在產品使用或過期後有資格獲得替換劑量。
Type 1 allergic reactions can be life-threatening, can happen in minutes, and can be caused by stinging and biting insects, foods, medication, exercise, or other unknown causes. Studies show that up to 18% of children with food allergies have had a reaction from accidentally eating food allergens while at school.1 In addition, 25% of severe and potentially life-threatening reactions (anaphylaxis) reported at schools happened in children with no previous diagnosis of food allergy.1
I型過敏反應可能危及生命，可以在幾分鐘內發生，可能是由蜇叮和咬傷的昆蟲、食物、藥物、運動或其他未知原因引起的。研究表明，多達18%的食物過敏兒童在學校裏意外食用食物過敏原時曾發生過敏反應。此外，在學校報告的25%嚴重且可能危及生命的反應（過敏性休克）發生在沒有食物過敏歷史的兒童身上。
譯文內容由第三人軟體翻譯。